Minimising Peripheral Neuropathy in Patients Treated With HAART

In This Article

Identify Those at Greatest Risk

Careful assessment of patients prior to the introduction of one of the potentially neurotoxic nucleoside analogues should be conducted to exclude those at greatest risk of developing peripheral neuropathy.[2]

Some of the most important risk factors for the development of nucleoside analogue-related peripheral neuropathy in HIV-infected individuals are outlined in table 2. The existence of any of these factors should be ascertained by taking a careful medical history, performing routine diagnostic procedures and examining the lower limbs for signs of peripheral neuropathy.

For 'at risk' patients or those with an equivocal clinical picture of peripheral neuropathy, nerve conduction studies may be helpful in determining whether to use didanosine, zalcitabine or stavudine.[2]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: